A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

New England Journal of Medicine

Volumn 344, Issue 9, 2001, Pages 619-625

  Turpie, Alexander G G ^a,d   Gallus, Alexander S ^b   Hoek, Jacob A ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c Sanofi Synthelabo Inc   (United Kingdom)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; PENTASACCHARIDE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHLEBOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; RISK BENEFIT ANALYSIS; TOTAL HIP PROSTHESIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0035283092     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103013440901     Document Type: Article

References (23)

1. Prevention of venous thromboembolism
2. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
3. Chemical synthesis of glycosaminoglycans: New approaches to antithrombotic drugs
4. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics
5. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: Resolution of the antithrombin conformational change contribution to heparin rate enhancement
6. Biochemical and pharmacological properties of SANORG 32701, comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31450) and standard heparin
7. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide
8. Relative contribution of factor Xa and factor IIA: Inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides
9. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide
10. The effect of the synthetic pentasaccharide SR90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa
11. On the antithrombotic action of heparin
12. Small doses of heparin and a new concept of hypercoagulability
13. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity
14. Lovenox (enoxaparin sodium injection)
15. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects
16. Good clinical practice for trials on medicinal products in the European community
17. Noninvasive diagnosis of deep venous thrombosis: McMaster Diagnostic Imaging Practice Guideline Initiative
18. Management of venous thromboembolism
19. Roentgen diagnosis of venous thrombosis in the leg
20. Sample size for a dose-response study
21. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
22. Prevention of deep vein thrombosis after hip replacement - Comparison of two low-molecular weight heparins, tinzaparin and enoxaparin
23. Prevention of venous thrombosis after elective hip surgery